Name

R-HyperCVAD

Alternate names

Hyper-CVAD + R

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for R-HyperCVAD

Name

Alternate Names

Aeroseb-Dex
AK-Dex
AK-Trol
Baldex
Component of Deronil
Component of Dexacidin
Component of Maxitrol
Dalalone
Decaderm
Decadrol
Decadron Tablets
Decajet
Decameth
Decasone
Decaspray
Deenar
Dex-4
Dexacen
Dexacidin
Dexacort Phosphate
Dexameth
Dexasone
Dexasporin
Dexone
Dexsone
Dezone
Gammacorten
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Infectrol Sterile
Maxidex
Maxitrol
Miral
Mymethasone
Neo-Dexameth
Neodecadron
Neodexair
Ocu-Trol
Oradexon
PMS-Dexamethasone Sodium Phosphate
SK-Dexamethasone
Sofracort
Sofradex
Solurex
Spersadex
Sterile Dexamethasone Acetate
Tobradex
Turbinare Decaron Phosphate

Abbreviations

DECA
DM
DSM

Category

Ancillary Agent
Hormones and hormonal mechanisms

Subcategory

Glucocorticoid. Probably not cancer directed--verify with attending MD.

NSC Number

345211

Primary Site

None

Histology

None

Remarks

NOTE* Dexamethasone may be coded as either an ancillary drug or hormone. Review chart to determine if given for supportive care or as hormonal therapy. IMPORTANT INFORMATION: dexamethasone is frequently included in treatment regimens, however, this does not indicate it should be coded as hormone therapy. Be sure to review the regimen tab in "Search Database" for additional coding information.

A long-acting corticosteroid (glucocorticoid). In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy. 25 times as potent as cortisol; used topically as an anti-inflammatory and administered orally in replacement therapy for adrenal insufficiency, as an anti-inflammatory and immunosuppressant in a wide variety of disorders, and as an antiemetic in cancer chemotherapy. Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for lymphoid leukemia, lymphoma and multiple myeloma.

Coding

Please see remarks for additional information

Name

Alternate Names

14-hydroxy-daunomycin
Adri-blastina (Italy)
Adriamycin
Adriamycin-TM
Caelyx
FT-106
Hydroxydaunomycin
Myocet
Pegylated Liposomal Doxorubicin Hcl
Rubex
S-DOX
Stealth(R) Liposomal Doxorubicin

Abbreviations

ADM
ADR
ADRI

Category

Chemotherapy

Subcategory

Antitumor antibiotic

NSC Number

123127

Primary Site

Bladder
breast
liver
multiple myeloma
ovarian
pancreatic
prostate cancer

Histology

None

Remarks

Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic

Coding

This drug should be coded

Name

Alternate Names

Anti-CD20 monoclonal antibodies
C2B8 monoclonal antibody
IDEC-C2B8
MabThera
Monoclonal antibody IDEC-C2B8
Rituxan

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Cytostatic monoclonal antibody

NSC Number

687451

Primary Site

Leukemia
NHL

Histology

None

Remarks

December 2, 2021 The FDA approved rituximab (Rituxan, Genentech, Inc.) in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.

FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.

FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.

FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.

FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieved response to rituximab in combination with chemotherapy.

June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.


.

Coding

This drug should be coded

Name

Alternate Names

D 7093
Mesna rescue
Mesnex
Mesnex uroprotection
Mesnum
Mistabron
Mitexan
Mucofluid
Sodium 2-mercaptoethanolsulfonate
UCB 3983
Uromitexan

Abbreviations

None

Category

Ancillary Agent

Subcategory

None

NSC Number

113891

Primary Site

None

Histology

None

Remarks

A prophylactic detoxifying agent used to inhibit hemorrhagic cystitis caused by ifosfamide. FDA approved for bladder protection when using cyclophosphamide (prevents bladder toxicity).

Coding

This drug should NOT be coded

Name

Alternate Names

Asta B 518
B-518
Clafen Claphene
Cyclophosphamid
Cyclophosphan
Cyclophosphane
Cytophosphan
Cytoxan
Endoxan
Endoxana
Enduxan
Genoxal
Neosar
Procytox
Sendoxan
Tymtram
WR-138719

Abbreviations

CP
CPM
CTX
CTY
CYC
Cyclo
CYT
CYTOX
CYTX

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

026271
26271

Primary Site

Breast
leukemia
lymphoma
multiple myeloma
neuroblastoma
ovarian cancer
retinoblastoma
soft tissue sarcoma
Wilm's tumor

Histology

None

Remarks

An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent

Coding

This drug should be coded

Name

Alternate Names

Compound 37231
Leurocristine Sulfate
Oncovin
Vincasar
Vincasar PFS
Vincristine Sulfate
Vincrystine
Vinkristin

Abbreviations

LCR
VCR
VNCR

Category

Chemotherapy

Subcategory

Plant alkyloid--antimetabolite

NSC Number

067574
67574

Primary Site

None

Histology

None

Remarks

Antineoplastic; vinca plant alkaloid; antimetabolite. FDA approved uses in ALL, Hodgkin's lymphoma, non-Hodgkin's lymphoma, neuroblastoma, rhabomyosarcoma, and Wilm's tumor.

Coding

This drug should be coded
Glossary